Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06396403
Other study ID # NL81111.018.22
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 13, 2023
Est. completion date December 2024

Study information

Verified date May 2024
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact Rajani P Brandsen, MD
Phone +31205669111
Email r.p.brandsen@amsterdamumc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Objective: to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics. Endpoints: The investigators will determine the difference in the above named parameters between patients with and without PSCR Study design: This case control study will include adult sickle cell disease patients with the HbSS or HbSC genotype. For both genotypes, 20 patients without sickle cell retinopathy (SCR) and 20 patients with PSCR will be included, resulting in a total of 80 patients. Venous blood samples and retinal imaging scans will be collected for each included patient.


Description:

Rationale: Sickle cell disease (SCD) is characterized by chronic hemolysis and recurrent microvascular occlusion, resulting in ischemia and organ damage1. This study focuses on retinal damage: sickle cell retinopathy (SCR). SCR results from ischemic vascular disease and secondary angiogenesis, but it is unknown which factors play a significant role in the pathogenesis. Studies on this subject are still in an early phase3,4. Our aim is to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics. The focus of our study is aimed at evaluation of innovative biomarkers of angiogenesis, whole blood viscosity and innovative characterization of red blood cell parameters such as deformability, adhesiveness and "point of sickling" as can be measured ex vivo by the Oxygenscan (i.e.: red cell sickling capacity). The Oxygenscan is a new method to calculate the deformability of red blood cells as a function of the partial pressure of oxygen. These novel parameters will be related to clinical characteristics observed in these patients and specific markers of early retinopathy such as vessel density and macula thinning assessed by OCT angiography. Objective: The objective of this study is to gain insight in the pathogenesis, to identify the role of red cell characteristics, markers of angiogenesis, retinal oxygenation and whole blood viscosity in the development of proliferative SCR and to investigate its associations with clinical and laboratory characteristics. Study design: Case control study Study population: Adult patients with sickle cell disease (SCD) with a HbSS or HbSC genotype. For both genotypes, 20 patients without SCR and 20 patients with proliferative SCR will be included. The total amount of included patients will be 80 patients. Intervention: venous blood samples (1 EDTA tube and 1 PECT tubes of 4-5 mL each) will be collected from all included patients, who will be requested to fast 8 hours before the collection of blood. If fasting is not desired/possible, a low-fat breakfast can be consumed. Main study parameters/endpoints: (1) The difference in red blood cell characteristics (point of sickling) between patients with and without PSCR, (2) The difference in plasma levels of parameters representing the level of systemic angiogenesis activity (CD105, VEGF, CTGF and angiopoietin-2) between patients with and without PSCR, (3) The difference in oxygenation of the retina by assessing the vessel density with angio-OCT and by assessing the oxygen saturation in the retinal arterioles and venules with the Oxymap scan in patients with and without PSCR, (4) The difference in whole blood viscosity between patients with and without PSCR Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Data from recent ophthalmologic and hematologic examinations will be collected. If no recent ophthalmologic examination is available and no further appointments were made yet, the patient will be contacted to visit the outpatient clinic for a new appointment. Since the appointments are in accordance with the general screening schedule according to the Dutch Guidelines for Sickle Cell Disease, these investigations are no extra burden for the patients. Venous blood samples will be obtained by venepuncture, preferably during the routine venepuncture for scheduled hematological visits (so the only extra burden consists of the extra blood aliquots that have be drawn to answer the research questions). Venepuncture is a safe and frequently used procedure in the routine care of patients with sickle cell disease. Due to the request to fast before the venepuncture, appointments will only be scheduled in the morning in order to reduce the burden on the patient as much as possible.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Minimum age of 18 years - HbSC or HbSS genotype - Recent ophthalmologic examination (up to 2 years prior) or (willingness to attend) upcoming examination Exclusion Criteria: - Age below 18 years - Genotype other than HbSC or HbSS - No recent ophthalmologic examination and no intention to visit the outpatient clinic for ophthalmic and hematologic examination - Participation in trials with either crizanlizumab, voxelotor or mitapivat.

Study Design


Intervention

Other:
Collection of venous blood samples
collection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL

Locations

Country Name City State
Netherlands Amsterdam UMC Amsterdam Noord-Holland

Sponsors (1)

Lead Sponsor Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Differences in Red blood cell characteristics (Oxygenscan) The difference in red blood cell characteristics (point of sickling) between patients with and without PSCR in both genotypes Immediately after the venepuncture
Primary Differences in Angiogenesis biomarkers The difference in plasma levels of parameters representing the level of systemic angiogenesis activity (CD105, VEGF, CTGF and angiopoietin-2) between patients with and without PSCR in both genotypes Immediately after the venepuncture
Primary Differences in Retinal Oxygenation The difference in oxygenation of the retina by assessing the vessel density with angio- OCT and by assessing the oxygen saturation in the retinal arterioles and venules with the Oxymap scan in patients with and without PSCR in both genotypes Immediately after the venepuncture
Primary Differences in Whole blood viscosity The difference in whole blood viscosity between patients with and without PSCR in both genotypes Immediately after the venepuncture
Secondary Associations between Oxygenation parameters and Red blood cell characteristics Association between retinal vessel density assessed by OCT-angiography, oxygen saturation assessed by an Oxymap scan and red blood cell characteristics (deformity, adhesion and point of sickling upon hypoxia) Immediately after the venepuncture
Secondary Associations between sex, age, and genotype and the biomarkers of angiogenesis Association between sex, age, and genotype and the biomarkers of angiogenesis Immediately after the venepuncture
Secondary Association between hemoglobin, and HbF and biomarkers of angiogenesis Association between hemoglobin, and HbF and biomarkers of angiogenesis Immediately after the venepuncture
Secondary Associations between whole blood viscosity and genotype Associations between whole blood viscosity and genotype Immediately after the venepuncture
See also
  Status Clinical Trial Phase
Completed NCT02227472 - Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
Recruiting NCT06301893 - Uganda Sickle Surveillance Study (US-3)
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT02522104 - Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Phase 4
Recruiting NCT04688411 - An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease N/A
Terminated NCT03615924 - Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Phase 3
Not yet recruiting NCT06300723 - Clinical Study of BRL-101 in Severe SCD N/A
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT04917783 - Health Literacy - Neurocognitive Screening in Pediatric SCD N/A
Completed NCT02580565 - Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04388241 - Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD N/A
Recruiting NCT05431088 - A Phase 2/3 Study in Adult and Pediatric Participants With SCD Phase 2/Phase 3
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Withdrawn NCT02960503 - Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease Phase 1/Phase 2
Completed NCT02620488 - A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease N/A
Not yet recruiting NCT02525107 - Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements Phase 3
Withdrawn NCT02630394 - A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease Phase 1